Our Executive Management

Ms. Zannes has more than 30 years of top executive-level management experience in industry. An attorney who specialized in regulatory law, she has worked as a top aide in the United States Congress, directed efforts leading to federal and state agency approvals, successfully lobbied numerous state legislatures, the Congress, and federal administrations. She was awarded the Lifetime Achievement Award by the American Society of Mechanical Engineers and Columbia University’s Earth Engineering Center Award. She is also the co-founder of two engineering research centers at Columbia University. Ms. Zannes received her J.D. from the University of Puget Sound in Washington State.

 

view list of articles

Mr. Girgenti is a veteran healthcare executive with a foundation in healthcare marketing strategies, financing, and mergers and acquisitions. He founded and ran several successful businesses, including Healthworld Corporation, a leading global healthcare marketing services network with more than $1 billion in billings and 55 offices in 35 countries. Mr. Girgenti was recognized as “Entrepreneur of the Year” by NASDAQ, and was named Med Ad News’ first “Medical Advertising Man of the Year.” Currently, he serves as a Director of Vycor Medical and is the Vice Chairman of the Board of Governors of the Mount Sinai Hospital Prostate Disease and Research Center in New York City. Mr. Girgenti graduated from Columbia University and is a registered pharmacist.

Dr. Rebel is a cancer (stem) cell biologist, with more than 20 years of experience in scientific research, focused on understanding the molecular events that lead to cancer development.  She received her M.D. and Ph.D. from the Free University in Amsterdam, The Netherlands, and post-doctoral training at the Dana-Farber Cancer Institute, Harvard Medical School.  From 2005 to 2016, she led her own research group at The University of Texas (UT) Health Science Center at San Antonio, where she first collaborated with bioAffinity.  Dr. Rebel received the 2012 Cancer Therapy and Research Center Discovery of the Year Award.  She is the (co)author of more than 40 publications in peer-reviewed journals.

Dr. Bauta is a medicinal chemist with more than 25 years of experience in discovery, development and commercialization of pharmaceuticals to treat oncology, virology, neuroscience, immunology and metabolic diseases. He joins bioAffinity Technologies from Southwest Research Institute where he helped develop the Institute’s pharmaceuticals services and bioengineering business. Dr. Bauta was Associate Director of Science at Genzyme Corporation and held a similar position at Ilex Products, Inc., where he was responsible for the discovery, development and FDA approval of multiple therapeutics. He holds several patents and has published in the journal Science and more than a dozen other scientific journals and conference proceedings. Dr. Bauta received his Ph.D. from the University of Chicago.

Mr. Edwards has more than 20 years of extensive experience in corporate finance and accounting, and has been providing CFO consulting services to biotechnology companies for the past eight years. Most recently, he was the CFO for CytoBioscience and previously he was the CFO for OncoVista Innovative Therapies. He was an assistant controller at ILEX Oncology, and controller at Bionumerik Pharmaceuticals and U.S. Global Investors. Mr. Edwards started his career at PricewaterhouseCoopers. He is a Certified Public Accountant and holds a Bachelor’s degree in business administration from The University of Texas at San Antonio and a Master’s degree from The University of Texas.

Our Board of Directors

Mr. Girgenti is a veteran healthcare executive with a foundation in healthcare marketing strategies, financing, and mergers and acquisitions. He founded and ran several successful businesses, including Healthworld Corporation, a leading global healthcare marketing services network with more than $1 billion in billings and 55 offices in 35 countries. Mr. Girgenti was recognized as “Entrepreneur of the Year” by NASDAQ, and was named Med Ad News’ first “Medical Advertising Man of the Year.” Currently, he serves as a Director of Vycor Medical and is the Vice Chairman of the Board of Governors of the Mount Sinai Hospital Prostate Disease and Research Center in New York City. Mr. Girgenti graduated from Columbia University and is a registered pharmacist.

Mr. Anderson has more than 40 years of broad experience the healthcare industry in which he held executive positions at CIBA, Becton Dickinson, Pfizer, Warner Lambert-Parke-Davis, Schering Plough and Centocor.   Mr. Anderson was Vice-President of Marketing for the Key Pharmaceuticals division of Schering-Plough and later at Centocor, a worldwide healthcare company now owned by Johnson & Johnson.  Mr. Anderson sat on the Executive Committee of Physicians World Communications Group (PWCG), where he was appointed as a Partner and Chief Operating Officer of the Company.  Mr. Anderson currently provides Executive Management services to a number of CEOs of healthcare companies.  Mr. Anderson received a B.A. in political science from Rutgers University and is a MENSA member.

Mr. Frankel is the Managing Director, Life Sciences, at Huron Consulting Group where he provides strategic solutions to pharmaceutical, device/diagnostic, biotechnology, healthcare intermediary and investment firms. He founded Frankel Group LLC in March 1993 that later was sold to Huron Consulting Group.  Mr. Frankel was President of SJ Weinstein Associates, an advertising and marketing strategy firm and also served in senior marketing and strategy positions at Pfizer Inc.  He holds a Masters in Business Administration with Distinction from The Wharton School, University of Pennsylvania, and a Bachelors of Science Summa Cum Laude in Engineering from Rutgers University.   Mr. Frankel is author of the article, The Current State of the Pharmaceutical Industry Research & Development: Four Part Series

Mr. Myron Holubiak is President and Chief Executive Officer of Leonard-Meron Biosciences, Inc., a drug development company in the field of critical medicine.  Mr. Holubiak also is Chairman of the Board of BioScrip, Inc., a leading infusion services provider with nationwide pharmacy and home nursing capabilities, and serves on the Board of Directors for Assembly Biosciences, Inc., where he is also chair of the Compensation Committee.  Mr. Holubiak is a senior partner and Director of 1-800-DOCTORS, Inc.  Mr. Holubiak is the former President of Roche Laboratories, Inc., and has served on the Board of Directors of Nastech Pharmaceutical Company, Inc. (now Marina Biotech, Inc.).  Along with Mr. Emery Dupuis, Mr. Holubiak was the co-founder of Emron, Inc.  Mr. Holubiak holds a BS degree in biophysics and molecular biology from the University of Pittsburgh with graduate work in biophysics.  He completed advanced executive training at Tuck’s School of Business at Dartmouth College, the Harvard Business School, the University of London, and the Centre for Health Economics at the University of York.

Mr. Rubin, a Certified Public Accountant, serves as a Managing Member of Masters Research Partners, LLC, an investment Fund of Hedge Funds that he co-founded in October 2000. Mr. Rubin began his career with Deloitte & Touche and later served as Managing Partner at Schissel, Rubin & Lehman, a New York based Certified Public Accounting firm. He has been involved in the investment business, including hedge funds, private equity and investment banking, for more than 20 years. Mr. Rubin is active in numerous charities as well as his Family’s foundation, and presently serves on the Board of Boca Raton Regional Hospital Foundation and the Finance committee of the Levitz Jewish Community Center, as well as serving as a Board Member for Family Promise of the Federation of South Palm Beach County. He graduated with a Bachelor of Science cum laude from SUNY at Buffalo, New York.

Dr. Squinto is a Venture Partner with OrbiMed Healthcare Fund Management. He previously co-founded Alexion Pharmaceuticals, Inc., a global biopharmaceutical company focused on the development and commercialization of breakthrough therapies for patients with rare and ultra-rare diseases. As Executive Vice President and Chief Global Operations Officer, Dr. Squinto helped build Alexion into a company currently valued at $25 billion. Prior to 2013, he served as head of Alexion’s Global Research and Development. From 1988 to 1992, Dr. Squinto held various positions at Regeneron Pharmaceuticals, Inc. Prior to Regeneron, he held a joint academic position at both the Tulane University and LSU Medical Schools. He is a recipient of numerous honors and awards from academic and professional organizations for his scientific work. Dr. Squinto received his B.A. in Chemistry and Ph.D. in Biochemistry and Biophysics from Loyola University of Chicago.

Ms. Zannes has more than 30 years of top executive-level management experience in industry. An attorney who specialized in regulatory law, she has worked as a top aide in the United States Congress, directed efforts leading to federal and state agency approvals, successfully lobbied numerous state legislatures, the Congress, and federal administrations. She was awarded the Lifetime Achievement Award by the American Society of Mechanical Engineers and Columbia University’s Earth Engineering Center Award. She is also the co-founder of two engineering research centers at Columbia University. Ms. Zannes received her J.D. from the University of Puget Sound in Washington State.

Our Scientists

Dr. Rebel is a cancer (stem) cell biologist, with more than 20 years of experience in scientific research, focused on understanding the molecular events that lead to cancer development.  She received her M.D. and Ph.D. from the Free University in Amsterdam, The Netherlands, and post-doctoral training at the Dana-Farber Cancer Institute, Harvard Medical School.  From 2005 to 2016, she led her own research group at The University of Texas (UT) Health Science Center at San Antonio, where she first collaborated with bioAffinity.  Dr. Rebel received the 2012 Cancer Therapy and Research Center Discovery of the Year Award.  She is the (co)author of more than 40 publications in peer-reviewed journals.

 

Dr. Rebel’s Publications >>

Dr. Bauta is a medicinal chemist with more than 25 years of experience in discovery, development and commercialization of pharmaceuticals to treat oncology, virology, neuroscience, immunology and metabolic diseases. He joins bioAffinity Technologies from Southwest Research Institute where he helped develop the Institute’s pharmaceuticals services and bioengineering business. Dr. Bauta was Associate Director of Science at Genzyme Corporation and held a similar position at Ilex Products, Inc., where he was responsible for the discovery, development and FDA approval of multiple therapeutics. He holds several patents and has published in the journal Science and more than a dozen other scientific journals and conference proceedings. Dr. Bauta received his Ph.D. from the University of Chicago.

 

Dr. Bauta’s Publications >>

Dr. Elzi brings 20 years of research experience to bioAffinity where he will continue to work on the mechanism of porphyrin uptake in cancer cells and expand CyPath®’s use with other cancers. Dr. Elzi earned his Ph.D. in Molecular and Cellular Biology from the University of Washington, in conjunction with the Fred Hutchinson Cancer Research Center.  He subsequently performed post-doctoral research at the Bonfils Blood Center and University of Colorado Department of Surgery, where he studied the molecular mechanisms of transfusion-related lung injury.  Dr. Elzi comes to bioAffinity from The UT Health Science Center where his research included applying proteomic techniques to study cellular senescence in primary and cancer cells.  He has published more than 20 peer-reviewed articles.

 

Dr. Elzi’s Publications >>

Mr. Reveles brings more than 25 years of experience as a clinical geneticist skilled in the creation and management of CLIA clinical laboratories, coding and CPT reimbursement valuations.  Mr. Reveles is board certified by the American Society of Clinical Pathology as a clinical specialist in cytogenetics. He was Laboratory Director for OncoPath Laboratory – START Cancer Center in San Antonio, Texas.  Mr. Reveles is (co)author of 15 publications and three abstracts in peer-reviewed journals.  He earned his Master’s Degree in biology/genetics from the University of The Incarnate Word in San Antonio, Texas.

 

Xavier T. Revels Publications >>

Dr. Sanchez brings 15 years of research experience to her work with bioAffinity on optimization and commercialization of CyPath® for early-stage lung cancer. She earned her Ph.D. in Cellular and Structural Biology at The UT Health Science Center where she gained extensive experience with fluorescence microscopy. Her earlier work with the Barshop Institute for Aging and Longevity Studies focused on associations between aging and cancer development.  Her emphasis on cancer research continued as a postdoctoral associate at The Greehey Children’s Cancer Research Institute under Dr. Rebel.  Dr. Sanchez has published five peer-reviewed papers with four additional manuscripts in preparation.

 

Dr. Sanchez’s Publications >>

Dr. Araujo completed her post-doctoral training as a molecular biologist at the University of Texas Health Science Center in San Antonio, Texas, where she investigated the networks formed by RNA binding proteins and miRNAs and their connection to biological processes and cancer.  She received her Doctorate from the Federal University of Minas Gerais, Belo Horizonte, Brazil and is an (co)author on more than 15 publications and a contributor to eight abstracts.

 

Dr. Araujo’s Publications >>

Dr. Bederka is a molecular virologist with an emphasis on viruses that cause hemorrhagic fever.  Dr. Bederka most recently worked as a post-doctoral fellow at the Texas Biomedical Research Institute where she performed high containment laboratory (BSL-4) studies for advancing the development of Ebola virus diagnostic assays. She received her Doctorate in Molecular Biology and Biochemistry from the University of California, in Irvine.

 

Dr. Bederka’s Publications >>

Dr. Lai completed his post-doctoral fellowship at Eastern Virginia Medical School in Norfolk, Virginia, where he focused on non-small cell lung carcinomas.  He earned his Doctorate in Molecular and Cellular Biology from the State University of New York Downstate Medical Center in Brooklyn, New York.  Dr. Lai has presented several projects at scientific events such as the Cold Spring Harbor Lab Symposium-Targeting Cancer including a research poster titled- TTF-1 (NKX2.1) modulates cholesterol metabolism and biosynthesis in lung cancer.  He has published eight peer-reviewed articles and one book chapter in Thyroid Hormone.

 

Dr. Lai’s Publications >>

Our Collaborations

bioAffinity Technologies works collaboratively with The University of Texas Health at San Antonio to advance research into the Company’s platform technology for the diagnosis and treatment of cancer.  One of the country’s leading health sciences universities, UT Health makes lives better with life-saving research, exceptional patient care and advanced academics in health care.   In addition to healthcare, education and community engagement, UT Health San Antonio champions research to develop life-saving advancements in treatment for cancer, aging and other serious conditions.  Its research facilities offer advanced equipment and services to provide researchers with the most advanced tools in the industry and provide patients with cutting-edge care.

Founded in 2000 by Madeleine Lemieux, PhD, Bioinfo specializes in high-throughput data analysis, mining, integration and visualization. Bioinfo provides bioAffinity Technologies with key insights and analysis of data and clinical results to advance the development and commercialization of the Company’s CyPath® test. Dr. Lemieux combines her training in computer science and stem cell biology to provide bioinformatics consulting services to clients. She works closely with the scientists at bioAffinity and The UT Health Science Center to better focus research on the CyPath® assay and support its commercialization.

bioAffinity Technologies works with Emergo, a global medical device consulting group with experience and access to the 24 largest medical device markets in the world, to advance the global commercialization of the Company’s technologies. Emergo provides strategic advice to ensure that CyPath® moves smoothly through global device registration, quality management system compliance, in-country regulatory representation, and reimbursement issues in all markets and countries.

Greenleaf Health LLC is a full-service regulatory consulting firm that provides strategic guidance to FDA-regulated companies that are developing innovative solutions to pressing public health challenges. bioAffinity Technologies is among a select group of clients in the healthcare sector seeking to advance breakthrough technologies that make a difference in the medical field. Daniel Schultz, MD, a former Director of the FDA’s Center for Devices and Radiological Health (CDRH), leads Greenleaf’s Medical Devices and Combination Products team. Together, these experts provide bioAffinity Technologies with strategic guidance on regulatory issues including pre-market review, product lifecycle management, manufacturing and compliance, and marketing and promotional practices within a rapidly changing regulatory environment.

Hyman, Phelps & McNamara is the largest dedicated FDA practice law firm in the country.  Founded in 1980, the firm was named the top FDA law firm by US News and World Report three years in a row.  In its medical devices and diagnostics practice area, Hyman, Phelps & McNamara helps clients understand all aspects of FDA’s regulation of medical device development, approval, clearance, manufacturing, post-market requirements, and marketing.  The firm works collaboratively with physicians and consultants to provide targeted medical and scientific expertise to help accomplish the regulatory goals of its clients.

Peacock Myers, P.C. has served as intellectual property counsel to bioAffinity Technologies since the Company’s incorporation. The law firm has helped build bioAffinity’s strong U.S. and international patent portfolio in 22 countries, including the U.S., EU, Canada, Australia, Japan, Mexico, China and Japan. Collaboration with the law firm has led to more than 45 awarded patents and four patents pending, with enforceable rights extending to 2030.  bioAffinity’s patent counsel, Janeen Vilven-Doggett, Ph.D., brings a scientific background to her practice of law, guiding innovative products to the marketplace by protecting proprietary technologies. Peacock Myers’ broad base of global connections has helped bioAffinity secure patent protection in all major markets.